Literature DB >> 2317815

Effects of androgen withdrawal on the stem cell composition of the Shionogi carcinoma.

N Bruchovsky1, P S Rennie, A J Coldman, S L Goldenberg, M To, D Lawson.   

Abstract

The parent Shionogi mouse mammary carcinoma is androgen dependent but cells that survive hormone withdrawal progress and give rise to an androgen-independent tumor. To determine whether renewed growth might be attributed to the persistence or partial recovery of an androgenic stimulus, we compared the amount of dihydrotestosterone and nuclear androgen receptor in parent and recurrent tumors. The whole tissue concentration of dihydrotestosterone in the parent tumor before castration was 1.40 +/- 0.46 (SE) as compared with 0.22 +/- 0.10 pmol/mg of DNA in the recurrent tumor. The initial concentration of nuclear androgen receptor in the parent was 0.65 +/- 0.12 pmol/mg of DNA; this was reduced to zero within 24 h after castration. Also in keeping with the androgen independence, no receptor was detected in the nuclear fraction of the recurrent carcinoma. In an attempt to relate malignant potential to nonhormonal factors associated with progression, we compared the proportions of androgen-dependent and -independent tumorigenic (stem) cells in parent and recurrent tumors using an in vivo limiting dilution assay. The difference observed, i.e., one stem cell per 4000 tumor cells in the parent versus one stem cell per 200 tumor cells in the recurrent carcinoma, was consistent with a marked enrichment of stem cells in the latter. The proportion of androgen-independent stem cells was also determined by assaying tumor takes in female hosts. The difference, i.e., one stem cell per 370,000 tumor cells in the parent versus one stem cell per 800 tumor cells in the recurrent carcinoma, demonstrated a striking 500-fold increase in androgen-independent stem cells resulting from androgen withdrawal. Unexpectedly, no enrichment of androgen-independent stem cells was evident in regressing parent tumors; rather, the proportion of such cells was very small, i.e., one androgen-independent stem cell per 2,200,000 regressing parent cells. This finding implies that the androgen-independent state of cells which survive androgen withdrawal may result from the ability of a small number of initially androgen-dependent stem cells to adapt to an altered hormone environment.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2317815

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  48 in total

Review 1.  Targeting anti-apoptotic genes upregulated by androgen withdrawal using antisense oligonucleotides to enhance androgen- and chemo-sensitivity in prostate cancer.

Authors:  Martin E Gleave; Toby Zellweger; Kim Chi; Hideaki Miyake; Satoshi Kiyama; Laura July; Simon Leung
Journal:  Invest New Drugs       Date:  2002-05       Impact factor: 3.850

2.  First pharmacophore-based identification of androgen receptor down-regulating agents: discovery of potent anti-prostate cancer agents.

Authors:  Puranik Purushottamachar; Aakanksha Khandelwal; Pankaj Chopra; Neha Maheshwari; Lalji K Gediya; Tadas S Vasaitis; Robert D Bruno; Omoshile O Clement; Vincent C O Njar
Journal:  Bioorg Med Chem       Date:  2007-03-13       Impact factor: 3.641

3.  The role of stress proteins in prostate cancer.

Authors:  Alan So; Boris Hadaschik; Richard Sowery; Martin Gleave
Journal:  Curr Genomics       Date:  2007-06       Impact factor: 2.236

4.  Prostate cancer: intermittent ADT--tales from a 27-year odyssey.

Authors:  Laurence Klotz
Journal:  Nat Rev Urol       Date:  2013-05-28       Impact factor: 14.432

5.  Efficacy of intermittent androgen deprivation therapy vs conventional continuous androgen deprivation therapy for advanced prostate cancer: a meta-analysis.

Authors:  Huei-Ting Tsai; David F Penson; Kepher H Makambi; John H Lynch; Stephen K Van Den Eeden; Arnold L Potosky
Journal:  Urology       Date:  2013-08       Impact factor: 2.649

Review 6.  The role of intermittent androgen deprivation therapy in the management of biochemically recurrent or metastatic prostate cancer.

Authors:  Jasbir Jaswal; Juanita Crook
Journal:  Curr Urol Rep       Date:  2015-03       Impact factor: 3.092

7.  Preliminary results of bicalutamide monotherapy on biochemical failure of localized prostate cancer.

Authors:  Fadil Akyol; Ugur Selek; Gokhan Ozyigit; Cem Onal; Bulent Akdogan; Erdem Karabulut; Haluk Ozen
Journal:  J Natl Med Assoc       Date:  2006-07       Impact factor: 1.798

Review 8.  [Androgen deprivation for advanced prostate cancer].

Authors:  A Heidenreich; D Pfister; C H Ohlmann; U H Engelmann
Journal:  Urologe A       Date:  2008-03       Impact factor: 0.639

Review 9.  Intermittent versus continuous androgen deprivation therapy in advanced prostate cancer.

Authors:  Laurence Klotz
Journal:  Curr Urol Rep       Date:  2013-06       Impact factor: 3.092

10.  Androgen deprivation therapy in advanced prostate cancer: is intermittent therapy the new standard of care?

Authors:  L Klotz; P Toren
Journal:  Curr Oncol       Date:  2012-12       Impact factor: 3.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.